Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience demonstrates a strong positive outlook primarily due to the advancements in its clinical assets, particularly ALTO-207 (CTC-501), which has shown improved tolerability against pramipexole, resulting in the capability for higher dosing and faster titration, potentially enhancing treatment outcomes for depressive symptoms. The company's recent financial performance is notable, with ALTO-207 generating $1.08 billion in revenue for FY24, reflecting a significant increase of approximately 60% compared to FY23. Additionally, the development of a new transdermal formulation for ALTO-101 is expected to enhance its safety profile and systemic exposure, further supporting ongoing studies and increasing confidence in the overall precision psychiatry pipeline.

Bears say

Alto Neuroscience Inc has faced significant headwinds since its IPO in 2024, primarily due to the failure of its lead asset, ALTO-100, in a critical Phase 2b study targeting major depressive disorder, compounded by negative data from ALTO-300. The failure of ALTO-100 raises serious concerns about the efficacy of the company's approach, particularly given the linkage between cognitive deficits in patients and poorer treatment outcomes, which may hinder future advancements. Despite ongoing studies in bipolar depression, the overall outlook remains bleak as previous clinical readouts have disappointed, suggesting a low probability of success for current and future assets.

ANRO has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Buy based on their latest research and market trends.

According to 6 analysts, ANRO has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.